drugset / Trial / NCT02755753

A Study to Evaluate REbamiPide as an Adjuvant Regimen to Heal erosIve Reflux Esophagitis

NCT02755753

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate whether Rebamipide facilitate the healing of inflamed mucosa as an adjuvant regimen in erosive reflux esophagitis (ERE).

Timeline

Start
2014-01
Primary completion
2016-01
Completion
2016-04

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Rebamipide Small molecule 100 mg Oral
Background Lansoprazole Other / unclassified 30 mg Oral